<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105191</url>
  </required_header>
  <id_info>
    <org_study_id>SRB2019_401</org_study_id>
    <nct_id>NCT05105191</nct_id>
  </id_info>
  <brief_title>Analytical Performances and Clinical Impact of the Roche Cobas速 Liat Influenza A/B &amp; RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room</brief_title>
  <official_title>Analytical Performances and Clinical Impact of the Roche Cobas速 Liat Influenza A/B &amp; RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LHUB-ULB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular techniques for respiratory virus detection have already shown benefits in terms of&#xD;
      sensitivity gained in comparison to conventional techniques. Recent progress has made it&#xD;
      possible to shorten turnaround time (TAT) and to allow delivery of results in a timely&#xD;
      manner, especially in comparison to cell culture and direct fluorescence assays (DFA).&#xD;
      However, the cost of these molecular assays is usually not taken in charge by public health&#xD;
      insurance system. This could be partly explained by the fact that molecular techniques have&#xD;
      not clearly shown cost-effectiveness. Results of molecular tests for influenza viruses and&#xD;
      RSV, if delivered rapidly, in the emergency room (ER), would most likely help avoid&#xD;
      antibiotic use and ancillary test prescription, improve antiviral prescription and shorten&#xD;
      length of stay in the ward by facilitating discharge or cohorting of hospitalized patients.&#xD;
      The goal of this study is to assess the performances of Roche Cobas速 Liat Influenza A/B &amp; RSV&#xD;
      assay, to appraise its clinical impact and to evaluate its cost effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID-19 pandemic introduced a confusion bias&#xD;
  </why_stopped>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analytical performance (Sensitivity/Specificity)</measure>
    <time_frame>through study completion, 6 months</time_frame>
    <description>Calculation of sensitivity and specificity of the test versus a composite reference standard. Samples are considered as positive for a viral pathogen if testing positive for this viral pathogen by at least 2 of the 3 techniques used, negative if tested negative by at least 2 of the 3 techniques (culture, antigen detection and PCR test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital admission intentions</measure>
    <time_frame>through study completion, 6 months</time_frame>
    <description>Number of admission intentions before and after the test result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Isolation intentions</measure>
    <time_frame>through study completion, 6 months</time_frame>
    <description>Number of isolation intentions before and after the test result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibiotic prescription intentions</measure>
    <time_frame>through study completion, 6 months</time_frame>
    <description>Number of antibiotic prescription intentions before and after the test result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral treatment prescription intentions</measure>
    <time_frame>through study completion, 6 months</time_frame>
    <description>Number of antiviral treatments prescription intentions before and after the test result</description>
  </primary_outcome>
  <enrollment type="Actual">280</enrollment>
  <condition>Influenza Viral Infections</condition>
  <condition>RSV Infection</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Roche Cobas速 Liat Influenza A/B &amp; RSV assay</intervention_name>
    <description>Performance of a rapid molecular assay to diagnose influenza and RSV infections</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Either a pre-test indication of hospitalization&#xD;
&#xD;
          -  or an underlying situation at risk of respiratory complication following influenza&#xD;
             infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brugmann Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Pierre Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

